Intermediate and long-acting insulins: A review of NPH insulin, insulin glargine and insulin detemir

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2613-2619

  Peterson, Gregory E ^a  

^a DES MOINES UNIVERSITY   (United States)

Author keywords

Glycemic control; Hypoglycemic; Insulin analogs; Insulin detemir; Insulin glargine; Long acting insulins

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ANTIBODY PRODUCTION; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; LIVER INJURY; MAXIMUM ALLOWABLE CONCENTRATION; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; STEADY STATE; WEIGHT GAIN;

DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; TREATMENT OUTCOME;

EID: 33845965337     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X154178     Document Type: Review

References (59)

1. The Diabetes Control and Complications Trial Research Group. The absence of a glycaemic threshold for the development of long-term complications. Diabetes 1996;45:1289-98
2. Reichard O, Nilsson BY, Rosenqvist U, et al. The effect of long-term intensified insulin treatment in the development of microvascular complications of diabetes mellitus. New Engl J Med 1993;329:304-9
3. Wang PH, Lau J, Chalmers TC, et al. Meta-analysis of effects of intensive blood-glucose control on late complications of Type I diabetes. Lancet 1993;341:1306-9
4. The Diabetes Control and Complications Trial Research Group. Hypoglycaemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-86
5. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 2005;353:2643-53
6. Stratton IM, Adler AI, Neil HA, et al. Association with glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12
7. Starke A, Heineman L, Hohlman A, Berger M. The action profiles of human NPH insulin preparations. Diabetic Med 1989;6:239-44
8. Kolendorf K, Bojsen J, Deckert T. Clinical factors influencing the absorption of 1251-NPH insulin in diabetic patients. Horm Metab Res 1983;15:274-8
9. Jehle PM, Micheler C, Jehle CR, et al. Inadequate suspension of neutral protamine Hagedorn insulin in pens. Lancet 1999;354:307-35
10. Bolli GB, Perriello G, Fanelli CG, De Feo P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care 1993;16:71-89
11. Home PD, Lindholm A, Riis A. Insulin aspart versus human insulin in the management of long-term blood glucose control in type I diabetes mellitus: a randomized controlled trial. Diabetic Med 2000;17:762-71
12. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analogue as the mealtime insulin in the management of patients with Type I diabetes. Diabetes Care 2000;23:583-8
13. Lindholm A, McEwen J, Riis AP. Improved post-prandial glycemic control with insulin aspart. Diabetes Care 1999;22:801-5
14. The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988;11:567-73
15. Purnell JQ, Hokanson JE, Marcvina SM, et al. Effect of excessive weight gain with intensive therapy of type I diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and complications Trial. J Am Med Assoc 1998;280:140-6
16. Williams KV, Erbey JR, Becker D, et al. Can clinical factors estimate insulin resistance in type I diabetes? Diabetes 2000;49:626-32
17. Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:4037-43
18. Fritsche A, Haring H. At last, a weight neutral insulin? Int J Obesity 2004;28:41-6
19. Bolli GB, Owens DR. Insulin glargine. Lancet 2000;356:443-5
20. Heinemann L, Linkeschova R, Rave K, et al. Time action profile of the long-acting insulin analog insulin glargine in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
21. Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with Type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004;66:49-56
22. Lindholm A. New insulins in the treatment of diabetes mellitus. Bedst Tract Res Clin Gastroenterol 2002;16:475-92
23. Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of insulins acylated with fatty acids. Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995;312:725-32
24. Markussen J, Havelund S, Kurtzhals P, et al. Soluble fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996;39:281-8
25. Kurzthals P. Engineering predictability and protraction in a basal insulin analog: the pharmacology of insulin detemir. Int J Obes 2004;28(Suppl. 2):23-8
26. Kruszynska YT, Home PD, Hanning I, Alberti KG. Basal and 24-h-C-peptide and insulin secretion in normal man. Diabetologia 1987;30:16-21
27. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patters of insulin secretion in non-insulin-dependent diabetes mellitus. New Engl J Med 1988;318:1231-9
28. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107-12
29. Heineman L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog Insulin Glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
30. Bott S, Tusek C, Jacobsen L, et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administrations in subjects with Type 1 diabetes. Diabetes Med 2006;23:522-8
31. Product information: LEVEMIR (insulin detemir injection). Princeton (NJ): Novo Nordisk, Inc.; 2005
32. Product information: LANTUS (insulin glargine injection). Bridgewater (NJ): Aventis Inc.; 2001
33. Heise T, Nosek L, Billman B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with Type 1 diabetes. Diabetes 2004;53:1614-20
34. Klein O, Lynge J, Endahl L, et al. Insulin detemir and insulin glargine: similar time-action profiles in subjects with type 2 diabetes. Diabetes 2006;55(Suppl. 1):A76
35. Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentrations and blood glucose responses after injection of regular insulin and various insulin mixtures. Diabetes Care 1981;4:366-76
36. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006;7:325-43
37. Scholtz HE, van Niekerk M, Meyer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Diabetologia 1999;42(Suppl. 1):A235
38. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type I diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7
39. Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36
40. Robertson K, Schonle E, Gucev Z, et al. Benefits of insulin detemir over NPH insulin in children and adolescents with Type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia. Diabetes 2004;53(Suppl. 2):A144
41. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004;47:622-9
42. Kolendorf K, Pavlic-Renar I, Santeusanio F, et al. Insulin detemir is associated with lower risk of hypoglycemia than NPH insulin in people with Type 1 diabetes. Diabetes 2004;53(Suppl. 1):A130
43. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir versus morning plus bedtime NPH insulin. Diabetic Med 2005;22:850-7
44. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obesity Metab 2005;7:56-64
45. Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for Type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201
46. Hermansen K, Davies M, DErezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with Type 2 diabetes. Diabetes Care 2006;29:1269-74
47. Rosenstock J, Park G, Zimmerman J, et al.; for the US Insulin Glargine Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH in patients with Type 1 diabetes on multiple day insulin regimens. Diabetes Care 2000;23:42
48. Pieber TR, Eugene-Jolchine I, Derobert E, and the European Study Group of Type 1 diabetes. Efficacy and safety of HOE901 versus NPH insulin in patients with Type 1 diabetes. Diabetes Care 2000;23:157-62
49. Raskin P, Klaff L, Bergenstal T, et al. A 16-week comparison of the novel insulin, insulin glargine (HOE 901) and NPH insulin used with insulin lispro in patients with Type 1 diabetes. Diabetes Care 2000;23:1666-71
50. Ratner RE, Hirsch IB, Neifing JL, et al.; for the US Study Group of Insulin Glargine in Diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy in Type 1 diabetes. Diabetes Care 2000;23:639-43
51. Yki-Harvinen H, Dressler A, Ziemen M, for the HOE 901/3002 Study Group. Less hypoglycemia and better-post-dinner glucose control with bedtime insulin glargine than with bedtime NPH insulin during combination therapy in Type 2 diabetes. Diabetes Care 2000;23:1130-6
52. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
53. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9
54. Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003;63:1743-78
55. Pieber TR, Treichel HC, Robertson LI, et al. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in Type 1 diabetes. Diabetologia 2005;48(Suppl. 1):A92
56. Rosenstock J, Davies M, Home P, et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006;55(Suppl. 1):A132
57. Dornhorst A, Merilainen M, Ratzmann K-P. Insulin detemir with or without OAD improves glycaemic control and reduces hypoglycaemic episodes, without weight gain, in Type 2 diabetes patients previously treated with NPH or glargine: results from a German subgroup of PREDICTIVE. Diabetes 2006;55(Suppl. 1):A146
58. EMEA Committee for Medicinal Products for Human Use. European public assessment report for Levemir (insulin detemir) 2004; EMEA website /H/C/528
59. EMEA Committee for Medicinal Products for Human Use. European public assessment report for Optisulin (insulin glargine) 2005; EMEA website (www.emea.eu.int/humandocs/PDFs/EPAR/optisulin